Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

Blueprint Medicines Corporation (BPMC) is focused on developing transformational precision medicines to address genomically defined cancers and rare diseases.The company’s lead drug, Ayvakit/Ayvakyt (avapritinib), a kinase inhibitor, is approved for three rare cancer indications, both in the United States and the EU. The drug is approved for treating adults with PDGFRA Exon 18 mutant gastrointestinal stromal tumors, adults with advanced systemic mastocytosis and adults with indolent systemic mastocytosis (S ...